Frost & Sullivan Independent Equity Research
Kadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged.
![kadimastem kadimastem](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/kadimastem-nx7oemt1c8wss047nf483o5eheckep4vzxb2tdiv9y.jpg)
Company: Kadimastem Ltd.
Sector: Biotechnology
Report type: H1-2018 Update
Published on: 27 September, 2018